Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB668668,5-2,12
PKN64,7664,88-5,48
Msft0,13
Nokia4,68054,83851,20
IBM-0,33
Mercedes-Benz Group AG64,2464,27-0,11
PFE-0,33
03.12.2022 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 02.12.2022
Paion (PA8G.DE, Xetra)
Závěr k 2.12.2022 Změna (%) Změna (EUR) Objem obchodů (EUR)
0,891 3,13 0,03 21 928
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 04.12.2022
Popis společnosti
Obecné informace
Název společnostiPaion AG
TickerPA8
Kmenové akcie:Ordinary Shares
RICPA8G.DE
ISINDE000A0B65S3
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 30.09.2022 62
Akcie v oběhu k 30.06.2022 71 336 992
MěnaEUR
Kontaktní informace
UliceHeussstrasse 25
MěstoAACHEN
PSČ52078
ZeměGermany
Kontatní osobaRalf Penner
Funkce kontaktní osobyVice President Investor Relations / Public Relations
Telefon4 924 144 530
Fax492414453100
Kontatní telefon492 414 453 152

Business Summary: Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Paion AG revenues increased from EUR3.6M to EUR25.2M. Net income totaled EUR9.7M vs. loss of EUR10.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Financial Expenses decrease of 57% to EUR969K (expense), Financial Income increase from EUR0K to EUR11K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Offices of Other Holding Companies
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Offices of Other Holding Companies
SICPharmaceutical Preparations
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 04.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardJoerg Spiekerkoetter6319.05.201006.08.2008
Chairman of the Management Board, Chief Executive OfficerJames Phillips5716.10.201916.10.2019
Deputy Chairman of the Supervisory BoardKarin Dorrepaal6129.10.201229.10.2012
Chief Financial Officer, Member of the Management BoardAbdelghani Omari4501.09.201401.09.2014